Clinical Trials for Type 1 Diabetes

126 type 1 diabetes trials indexed, 55 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding Type 1 Diabetes

Type 1 diabetes is a chronic condition where the body's immune system attacks and destroys insulin-producing cells in the pancreas. Insulin is a hormone that helps regulate blood sugar levels by allowing glucose to enter cells for energy. Without enough insulin, glucose builds up in the bloodstream, leading to high blood sugar. Diagnosis usually involves blood tests that measure blood sugar levels, such as fasting plasma glucose or the hemoglobin A1c test, which reflects average blood sugar over several months. Doctors may also check for autoantibodies that signal an immune attack on the pancreas.

Common symptoms of type 1 diabetes include increased thirst, frequent urination, extreme hunger, unintended weight loss, fatigue, and blurred vision. These symptoms often develop quickly, sometimes over weeks. Type 1 diabetes most often begins in children, teens, or young adults, but it can appear at any age. It affects about 5 to 10 percent of all people with diabetes. Risk factors include a family history of the disease, certain genetic markers, and possibly environmental triggers like viral infections, although the exact cause is not fully understood.

Type 1 diabetes matters medically and socially because it requires lifelong management and can lead to serious complications if not controlled. Approximately 1.6 million Americans have type 1 diabetes, and it accounts for about 5 percent of all diagnosed diabetes cases in the United States. People with this condition face risks of heart disease, kidney problems, nerve damage, and vision loss. The economic burden is significant: the American Diabetes Association estimates that diagnosed diabetes costs the U.S. $327 billion annually, including medical expenses and lost productivity. Managing type 1 diabetes well is crucial to prevent these outcomes and maintain quality of life.

The Type 1 Diabetes Treatment Landscape

The first-line treatment for type 1 diabetes is insulin replacement therapy. Since the body no longer produces insulin, patients must receive it through injections or an insulin pump. Treatment is typically personalized to match blood sugar patterns and lifestyle. Patients monitor their blood glucose levels multiple times a day to adjust insulin doses and avoid both high and low blood sugar. Along with insulin, patients are advised to follow a balanced diet, exercise regularly, and manage stress to help control glucose levels.

Beyond insulin, other treatment options may be used to improve blood sugar control or address complications. For example, adjunctive drugs like amylin analogs can slow digestion and reduce blood sugar spikes after meals. Some patients may use continuous glucose monitors (CGMs) to provide real-time blood sugar readings, which help fine-tune insulin delivery. Research also explores immune therapies aimed at preserving remaining insulin-producing cells early in the disease. However, insulin remains the mainstay of treatment, with other medications playing supportive roles.

Despite advances, current treatments have gaps. Some patients struggle with frequent hypoglycemia or high blood sugar that is hard to control. Insulin therapy carries risks like weight gain and low blood sugar episodes. Also, managing type 1 diabetes demands constant attention, which can be burdensome. Research is focused on developing therapies that protect or restore insulin production, reduce immune system attacks, and improve glucose control with fewer side effects. Closing these gaps could ease daily management and reduce long-term complications.

Why Clinical Trials Matter for Type 1 Diabetes

Clinical trials offer patients opportunities to access new treatments that are not yet widely available. They also provide closer monitoring by healthcare teams and the chance to contribute to scientific knowledge that may help others in the future. There are currently 126 type 1 diabetes clinical trials indexed on ClinicalTrials.gov, with 55 actively recruiting participants. These studies explore various approaches, from new insulin delivery methods to immune therapies and beta cell regeneration. Participation can be a way to stay informed about emerging options and receive care that follows strict research protocols.

It is important to understand that clinical trials carry risks. The effectiveness of new treatments is not guaranteed, and some participants may receive a placebo instead of the experimental drug. Trials often require additional clinic visits and tests, which can be time-consuming. Side effects or unexpected reactions may occur, as the safety profile of new therapies is still under evaluation. Patients should carefully discuss the potential risks and benefits with their healthcare providers before enrolling in a study.

The sponsors of type 1 diabetes clinical trials include academic research centers, pharmaceutical companies, and cooperative research groups. These organizations work together to design and conduct studies that address different aspects of the disease. ClinicalTrials.gov serves as a public registry to list ongoing and completed trials, making it easier for patients and doctors to find relevant studies. This transparency helps ensure that research is conducted ethically and that results are shared with the wider community.

What to Look for in a Type 1 Diabetes Clinical Trial

Clinical trials for Type 1 Diabetes are organized into phases 1 through 4, each serving a different purpose. Phase 1 trials test safety and dosage with a small group of participants. Phase 2 trials assess the effectiveness and side effects on a larger group. Phase 3 trials confirm results in an even larger population and compare the new treatment to current standards. Phase 4 trials occur after approval to monitor long-term effects. For Type 1 Diabetes, many trials are not assigned a specific phase (52), while Phase 2 trials are the most common (14). There are also 9 Phase 1 trials and 5 Phase 3 trials active or indexed currently.

Inclusion criteria for Type 1 Diabetes trials often focus on specific factors related to the disease. Age is a common factor, with many studies targeting children, adolescents, or adults separately. Prior treatments may be considered, such as insulin regimen or use of immunotherapies. Biomarkers like autoantibodies or C-peptide levels can help identify participants in certain disease stages. Disease duration is also important; some trials seek newly diagnosed individuals, while others focus on those with longer disease history. These criteria help ensure the study results apply to the intended group.

Exclusion criteria are designed to protect participants and maintain clear study results. People with other serious medical conditions, such as heart or kidney disease, may be excluded to avoid complications. Potential drug interactions with current medications are also considered to prevent harmful effects. Safety thresholds, like abnormal lab values or recent infections, can disqualify participants to reduce risks. These rules help keep the trial safe and the data reliable.

From a practical standpoint, patients should consider the trial duration and visit schedule. Some studies may last months or years, requiring frequent visits to the clinic. Travel to specialized centers can be a challenge, especially if the site is far from home. It is important to ask the research team clear questions: How many visits are required and how long will each last? What procedures or tests will be done during visits? Are there any costs or reimbursements for travel and time? What are the potential risks and benefits of participating? Being informed helps patients and caregivers decide if a trial fits their needs and lifestyle.

Primary Sources and Further Reading

For more detailed information about Type 1 Diabetes and clinical trials, it is helpful to consult trusted sources. These websites provide reliable medical information, guidance on research participation, and updates on ongoing studies. Patients and caregivers can use these resources to learn more about the condition and how clinical trials work.

Latest Research and Emerging Treatments for Type 1 Diabetes (2026)

New drugs for type 1 diabetes are being tested in several Phase 3 clinical trials. One example is Diamyd, an immunotherapy injection that aims to preserve insulin production in people newly diagnosed with type 1 diabetes (NCT05018585). Diamyd contains a protein called glutamic acid decarboxylase, which may help calm the immune system and protect insulin-producing cells. If successful, this type 1 diabetes new treatment 2026 could improve blood sugar control and reduce the need for insulin injections.

Another promising area of type 1 diabetes research involves immune system modulation. Teplizumab is an antibody treatment being studied in young patients aged 1 to 25 years (NCT07088068). It works by targeting immune cells that attack the pancreas, potentially slowing disease progression. Patients receiving teplizumab may experience better blood sugar levels and less dependence on insulin over one year of treatment.

For people with type 1 diabetes who have had a kidney transplant, VX-880 is being tested as a biological therapy (NCT06832410). This treatment involves transplanting insulin-producing cells to restore natural insulin production. Early data suggests it could reduce or eliminate the need for insulin injections, improving quality of life. These studies reflect ongoing efforts to expand type 1 diabetes treatment options beyond insulin and address the underlying causes of the disease.

Frequently asked questions about Type 1 Diabetes trials

How do I find Type 1 Diabetes clinical trials?

The authoritative source for Type 1 Diabetes clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 126 type 1 diabetes studies are currently indexed. You can search by entering "type 1 diabetes" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new type 1 diabetes trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most Type 1 Diabetes trials in?

Across the 126 type 1 diabetes trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many Type 1 Diabetes clinical trials are currently recruiting?

As of the latest scan, 55 type 1 diabetes trials have a "Recruiting" status on ClinicalTrials.gov, out of 126 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting type 1 diabetes trial matches their tracked condition.

Stay informed about type 1 diabetes research

Get a weekly briefing with the trials that matter most.

Start monitoring type 1 diabetes trials